We recently completed a new research update on Viral Genetics which is a very small quasi-public company emerging from a quiet year with much more planned in 2012. [Click to access the PDF of our Viral Update Report March 6, 2012.]
Since we published the report just a day or two ago the company announced their first Pre-IND submission to the FDA for the treatment of Lyme Disease. The company has also published some of their plans for the year in their recent letter to shareholders which is available via this link (PDF).
As noted in our research update and prior research reports Viral Genetics has strong fundamental science that has broad applications in medicine and even energy. The company has built a strong patent portfolio supporting two distinct platform technologies (Metabolic Disruption and Targeted Peptides) since 1994. Besides developing applications themselves they are also working on licensing their core patents to be used in different drug therapies.
To do all this the company is actively seeking capital and interested investors should contact the company directly for more information. As they begin to spend more time in the clinic and attract development and licensing partners we believe they will find an easier time attracting capital and can improve their balance sheet and rationalize their share capital. This is after all a long-term investment story suitable to institutions.
[We have advised the company on strategy and investor positioning but are not in any way working with them on structuring their financing or promoting it to investors. We have evaluated the science and the prospective applications only. No information provided should be relied upon by anyone in making an investment decision. We are not a broker/dealer or investment bank and are making no solicitation.]